The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors. AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the…
Overview Cardiex Limited (ASX:CDX) is an ASX-listed medical technology company leveraging its proprietary SphygmoCor® technology to develop and market…
Victory Battery Metals CORP. (CSE:VR)(OTC PINK:VRCFF)(FWB:VR6) is pleased to announce that it has entered into an option agreement dated…
Vizsla Copper Corp. (TSXV: VCU) (‘ Vizsla Copper ‘) and Universal Copper Ltd. (TSXV: UNV) (‘ Universal Copper ‘)…
(TheNewswire) Payment date for the distribution will be April 26, 2024 Coquitlam, BC TheNewswire – April 18, 2024 –…
Major diversified miner Rio Tinto (ASX:RIO,NYSE:RIO,LSE:RIO) weathered both operational challenges and a tragic loss to deliver a resilient performance…
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / Awalé Resources (TSXV:…
Manuka Resources Limited (ASX: MKR) (“Manuka” or the “Company”) is pleased to release an updated Mineral Resources Estimate for…